Bridgetech acquires Asian rights to cancer drugs

Bridgetech will have the right to manufacture and distribute these products throughout the Peoples Republic of China, Hong Kong, Macau and Taiwan. Bridgetech will also receive rights to two promising antibiotics and first right of refusal for Asian rights on future oncology therapeutics.

The current versions of the cancer drugs, docetaxel and paclitaxel, utilize detergents to breakdown their compounds into injectable form. This bleach causes serious side effects. The three days of immune system suppression required to precede these therapies also poses serious risks for cancer patients. Bridgetech’s compounds utilize a new nano-emulsion formulation. Not only does this effectively remove the toxicity but it allows for significant dosage increases because of the lack of normal side effects.

“The first of the four key components of our business strategy is getting the best science. That is exactly what we have done with these two new compounds. Basically, these products are non-toxic versions of FDA approved chemo agents that are currently among the top selling cancer drugs in China,” commented Michael Chermak, chairman and CEO of Bridgetech.